ASCO 2026 | New approaches to curing bladder and kidney cancers: where do we stand?
Srikala Sridhar, MD, Princess Margaret Cancer Centre, Toronto, Canada, shares insight into recent advances in bladder and kidney cancer treatments, highlighting the potential of the EV-101 regimen in changing the paradigm for these diseases. Dr Sridhar notes that this regimen has shown improved event-free survival, overall survival, and pathologic complete response rates, and emphasizes the importance of defining these approaches and integrating different therapies to improve patient outcomes. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
